The Burden of Neurologic Disorders in Canada, 1990–2023: A Systematic Analysis in the Global Burden of Disease Study 2023

BACKGROUND AND OBJECTIVES: Neurologic disorders are leading contributors to global disability and mortality, yet Canada-specific burden estimates have not been updated with the most recent Global Burden of Disease (GBD) data. We aimed to quantify the burden of 18 neurologic conditions in Canada in 2023, characterize trends from 1990 to 2023, describe age-specific and sex-specific patterns, and compare Canada with the high-income country average. METHODS: This retrospective epidemiologic modeling study analyzed GBD 2023 data for Canada. Eighteen conditions whose primary health loss manifestation directly affects the central or peripheral nervous system were included. Outcome measures included prevalence, mortality, and disability-adjusted life years (DALYs) comprising years lived with disability (YLDs) and years of life lost (YLL). Age-standardized rates are all per 100,000 population. 95% uncertainty intervals (UI) are reported for all estimates. RESULTS: Modeling evaluated the entire Canadian population across 34 years. In 2023, neurologic disorders accounted for 11.48% (UI: 9.47-14.26) of total DALYs and 16.31% (UI: 10.56-26.24) of deaths. Burden was heavily driven by nonfatal disability metrics (YLDs); Alzheimer disease and other dementias led absolute DALYs at 366,548.5 (UI: 180,491.8-710,281.4), followed by migraine at 232,619.5 (UI: 151,390.4-320,391.1) and ischemic stroke at 223,748.0 (UI: 194,981.3-249,309.6). Migraine led age-standardized DALY rates at 565.8 (UI: 374.0-783.1) per 100,000, driven entirely by nonfatal disability metrics. Dementias drove mortality with 20,108.6 (UI: 4,999.6-50,266.6) deaths. From 1990 to 2023, the steepest age-standardized DALY rate increases occurred in other neurologic disorders (153.6% [UI: 129.0-185.1]), encephalitis (59.2% [UI: 25.1-95.6]), and Parkinson disease (25.4% [UI: 18.9-33.0]), while meningitis declined by 62.6% (UI: 57.4-66.9). DISCUSSION: Neurologic disorders present a substantial public health challenge in Canada, marked by widespread midlife nonfatal disability from migraine and escalating late-life neurodegeneration. Over 3 decades, the national burden shifted toward chronic neurodegenerative diseases. These findings highlight the need for national strategies to expand care capacity and address chronic disability. A key limitation of this analysis is that GBD estimates for Canada are currently restricted to the national level; because Canada is a vast, geographically and demographically diverse nation, country-wide aggregates do not elucidate critical subnational disparities.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-11-16
DOI
https://doi.org/10.1212/wnl.0000000000218702
Primary Topic
Global Health and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Burden of Neurologic Disorders in Canada, 1990–2023: A Systematic Analysis in the Global Burden of Disease Study 2023

Sarah Eshafi, Silke Appel‐Cresswell, Seyed‐Mohammad Fereshtehnejad, Amirali Aali et al.
1 links
Neurology
Global Health and Epidemiology
article

The Burden of Neurologic Disorders in Canada, 1990–2023: A Systematic Analysis in the Global Burden of Disease Study 2023

Sarah Eshafi, Silke Appel‐Cresswell, Seyed‐Mohammad Fereshtehnejad, Amirali Aali, Joyce S. T. Lam, Samantha Schaffner
article en

Abstract

BACKGROUND AND OBJECTIVES: Neurologic disorders are leading contributors to global disability and mortality, yet Canada-specific burden estimates have not been updated with the most recent Global Burden of Disease (GBD) data. We aimed to quantify the burden of 18 neurologic conditions in Canada in 2023, characterize trends from 1990 to 2023, describe age-specific and sex-specific patterns, and compare Canada with the high-income country average. METHODS: This retrospective epidemiologic modeling study analyzed GBD 2023 data for Canada. Eighteen conditions whose primary health loss manifestation directly affects the central or peripheral nervous system were included. Outcome measures included prevalence, mortality, and disability-adjusted life years (DALYs) comprising years lived with disability (YLDs) and years of life lost (YLL). Age-standardized rates are all per 100,000 population. 95% uncertainty intervals (UI) are reported for all estimates. RESULTS: Modeling evaluated the entire Canadian population across 34 years. In 2023, neurologic disorders accounted for 11.48% (UI: 9.47-14.26) of total DALYs and 16.31% (UI: 10.56-26.24) of deaths. Burden was heavily driven by nonfatal disability metrics (YLDs); Alzheimer disease and other dementias led absolute DALYs at 366,548.5 (UI: 180,491.8-710,281.4), followed by migraine at 232,619.5 (UI: 151,390.4-320,391.1) and ischemic stroke at 223,748.0 (UI: 194,981.3-249,309.6). Migraine led age-standardized DALY rates at 565.8 (UI: 374.0-783.1) per 100,000, driven entirely by nonfatal disability metrics. Dementias drove mortality with 20,108.6 (UI: 4,999.6-50,266.6) deaths. From 1990 to 2023, the steepest age-standardized DALY rate increases occurred in other neurologic disorders (153.6% [UI: 129.0-185.1]), encephalitis (59.2% [UI: 25.1-95.6]), and Parkinson disease (25.4% [UI: 18.9-33.0]), while meningitis declined by 62.6% (UI: 57.4-66.9). DISCUSSION: Neurologic disorders present a substantial public health challenge in Canada, marked by widespread midlife nonfatal disability from migraine and escalating late-life neurodegeneration. Over 3 decades, the national burden shifted toward chronic neurodegenerative diseases. These findings highlight the need for national strategies to expand care capacity and address chronic disability. A key limitation of this analysis is that GBD estimates for Canada are currently restricted to the national level; because Canada is a vast, geographically and demographically diverse nation, country-wide aggregates do not elucidate critical subnational disparities.

NeurologyVol. 107(11)
University of British Columbia (CA), Djavad Mowafaghian Centre for Brain Health (CA)
Good health and well-being
Global Health and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon